{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/AMPH/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T02:28:14.989Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":10017,"canonical_name":"Amphastar Pharmaceuticals, Inc.","cik":"0001297184","uei":null,"lei":null,"duns":null,"ticker":"AMPH"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":27,"clinical":1},"count":28,"timeline":[{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Amphastar Pharmaceuticals, Inc. — 2026-09-17","url_slug":"/sec/cik-0001297184/4/0001645326-26-000014","accession_number":"0001645326-26-000014","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Amphastar Pharmaceuticals, Inc. — 2026-09-03","url_slug":"/sec/cik-0001297184/4/0001645326-26-000012","accession_number":"0001645326-26-000012","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"144","title":"144 — Amphastar Pharmaceuticals, Inc. — 2026-09-01","url_slug":"/sec/cik-0001297184/144/0001969223-26-000982","accession_number":"0001969223-26-000982","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"144","title":"144 — Amphastar Pharmaceuticals, Inc. — 2026-08-18","url_slug":"/sec/cik-0001297184/144/0001969223-26-000926","accession_number":"0001969223-26-000926","importance":30},{"ts":"2026-08-11","kind":"sec.form144","reporter":"Richard Prins","title":"Director","shares":7973,"usd_value":161932,"security_title":"Common Stock","approx_sale_date":"2026-08-11","accession_number":"0001969223-26-000880","importance":40.032386326},{"ts":"2026-08-07","kind":"sec.insider.s","reporter":"PETERS WILLIAM J","title":"CFO, EVP & TREASURER","shares":8180,"price_per_share":22.48,"usd_value":183886,"security_title":"Common Stock","importance":35.1838864},{"ts":"2026-08-07","kind":"sec.insider.m","reporter":"PETERS WILLIAM J","title":"CFO, EVP & TREASURER","shares":5053,"price_per_share":19.79,"usd_value":99999,"security_title":"Common Stock","importance":15.09999887},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Amphastar Pharmaceuticals, Inc. — 2026-08-06","url_slug":"/sec/cik-0001297184/10-q/0001297184-26-000047","accession_number":"0001297184-26-000047","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Amphastar Pharmaceuticals, Inc. — 2026-08-06","url_slug":"/sec/cik-0001297184/8-k/0001297184-26-000045","accession_number":"0001297184-26-000045","importance":35},{"ts":"2026-07-14","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Amphastar Pharmaceuticals, Inc. — 2026-07-14","url_slug":"/sec/cik-0001297184/schedule-13g/0000354204-26-000782","accession_number":"0000354204-26-000782","importance":55},{"ts":"2026-07-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Amphastar Pharmaceuticals, Inc. — 2026-07-13","url_slug":"/sec/cik-0001297184/8-k/0001104659-26-082772","accession_number":"0001104659-26-082772","importance":35},{"ts":"2026-07-13","kind":"sec.filing","form_type":"3","title":"3 — Amphastar Pharmaceuticals, Inc. — 2026-07-13","url_slug":"/sec/cik-0001297184/3/0002141303-26-000003","accession_number":"0002141303-26-000003","importance":30},{"ts":"2026-07-13","kind":"sec.filing","form_type":"4","title":"4 — Amphastar Pharmaceuticals, Inc. — 2026-07-13","url_slug":"/sec/cik-0001297184/4/0002141303-26-000005","accession_number":"0002141303-26-000005","importance":30},{"ts":"2026-07-09","kind":"sec.insider.a","reporter":"Pierce Anthony T","title":"","shares":7886,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Amphastar Pharmaceuticals, Inc. — 2026-07-08","url_slug":"/sec/cik-0001297184/8-k/0001297184-26-000041","accession_number":"0001297184-26-000041","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"8-K","title":"8-K — Amphastar Pharmaceuticals, Inc. — 2026-06-03","url_slug":"/sec/cik-0001297184/8-k/0001297184-26-000038","accession_number":"0001297184-26-000038","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Amphastar Pharmaceuticals, Inc. — 2026-06-03","url_slug":"/sec/cik-0001297184/4/0001379941-26-000003","accession_number":"0001379941-26-000003","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Amphastar Pharmaceuticals, Inc. — 2026-06-03","url_slug":"/sec/cik-0001297184/4/0001611283-26-000003","accession_number":"0001611283-26-000003","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Amphastar Pharmaceuticals, Inc. — 2026-06-03","url_slug":"/sec/cik-0001297184/4/0001866024-26-000003","accession_number":"0001866024-26-000003","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Amphastar Pharmaceuticals, Inc. — 2026-06-03","url_slug":"/sec/cik-0001297184/4/0002075974-26-000003","accession_number":"0002075974-26-000003","importance":30},{"ts":"2026-06-02","kind":"sec.insider.f","reporter":"Lee Howard","title":"","shares":769,"price_per_share":18.45,"usd_value":14188,"security_title":"Common Stock","importance":15.01418805},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"ZASLOFF MICHAEL A","title":"","shares":8143,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"PRINS RICHARD K","title":"","shares":8143,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Lee Howard","title":"","shares":8143,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Gerst Diane G.","title":"","shares":8143,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Deflin Gayle","title":"","shares":8143,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Gaugh David Russell","title":"","shares":8143,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Amphastar Pharmaceuticals, Inc.","title":"Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07560150","excerpt":"[\"Pharmacokinetics\",\"Pharmacodynamics\",\"Insulin Aspart\"]","importance":60}]}